AXL mediates mast cell survival and resistance to tyrosine kinase inhibitors in mastocytosis
Kangboonruang K,Drabent P,Maksut F,Heintzé M,Lepelletier Y,Lhermitte L,Feroul M,Letard S,Kaboré C,Brenet F,Méni C,Cagnard N,Bondet V,Lefèvre G,Bruneau J,Dussiot M,Halse H,Bigorgne A,Collange A,Bouktit H,Rétornaz F,Megret J,Barete S,Droin N,Livideanu C,Lebouvier A,Duffy D,Solary E,Arock M,Gandhi D,Bodemer C,Rossignol J,Polivka L,Molina T,Hermine O,Maouche-Chrétien L
Source :
openRxiv
2025 Nov 4
Pmid / DOI:
10.1101/2025.11.03.686205
Abstract
Key Points – AXL is aberrantly expressed in neoplastic mast cells, driving survival and resistance to KIT inhibition in mastocytosis. – Dual KIT and AXL inhibition restores TKI sensitivity in KIT-mutant mastocytosis. Graphical abstract